非洲恶性疟原虫青蒿素部分耐药分子标记流行率的时空建模研究
研究提示青蒿素部分耐药在东非多中心快速扩张,威胁ACT疗效。
要点
- k13耐药突变在卢旺达、乌干达、埃塞俄比亚和厄立特里亚独立出现并快速扩张。
- k13突变与mdr1 N86Y或crt K76T共现地区ACT疗效风险更高,需优先监测。
核心结论
- k13青蒿素部分耐药突变在东非多中心快速扩张,威胁以青蒿素为基础的联合疗法疗效。
- k13突变与伴侣药物耐药标记共现地区风险更高,需靶向监测和疗效研究。
研究设计与样本
- 系统综述与时空高斯过程建模分析,检索PubMed、Ovid MEDLINE和Web of Science等数据库。
- 研究注册于PROSPERO(CRD42024593923)。
主要发现
- k13 R561H在卢旺达、A675V和C469Y在乌干达、R622I在埃塞俄比亚和厄立特里亚独立出现。
- k13耐药从局部出现快速转变为覆盖乌干达和卢旺达大部分地区的区域性热点。
- mdr1 N86Y流行率下降,crt K76T在非洲之角仍流行。
临床怎么用
- 利用高分辨率耐药地图识别k13突变热点,指导靶向监测。
- 在k13与mdr1 N86Y或crt K76T共现地区优先开展治疗疗效研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plasmodium falciparum kelch13(k13) mutations in Africa signal emerging artemisinin partial resistance (ART-R), endangering malaria control by undermining artemisinin-based combination therapies (ACTs). Sparse surveillance obscures whether rising k13 ART-R prevalence reflects local emergence or geographical expansion. We aimed to model and infer high-resolution spatiotemporal prevalence of k13 ART-R mutations, as well as mdr1 and crt mutations (markers of reduced susceptibility to ACT partner drugs), to inform public health policy. METHODS: For this systematic review and modelling analysis, we searched PubMed, Ovid MEDLINE, and Web of Science databases for English-language primary studies reporting malaria resistance, conducted in Africa, reporting pretreatment P falciparum samples with genotyping of k13 (all codons), mdr1 N86Y, or crt K76T, and that provided sufficient survey time and location metadata and complete, primary data, published between Sept 25, 2014, and July 9, 2025, with data extracted from full-text reports. Studies identified during the systematic review were added to 11 privately held datasets that met the same eligibility criteria but were unpublished at the time of review to give the augmented systematic review. Studies from the augmented systematic review were added to existing data from the Worldwide Antimalarial Resistance Network molecular surveyor (WWARN), MalariaGEN Pf8, and the WHO malaria threats map (WHO MTM), with any duplicates removed. The integrated dataset was harmonised by use of a standardised data schema. We estimated the continuous prevalence of each mutation using a spatiotemporal Gaussian process model and summarised with median and 95% credible intervals over posterior draws. The study was registered with PROSPERO (CRD42024593923). FINDINGS: We identified 1119 articles during the database search, with 120 studies included in the final analysis. These were augmented with 11 privately held datasets. In total, the augmented systematic review identified 131 unique studies. Data from public repositories (WWARN, Pf8, and WHO MTM) provided an additional 447 studies after removal of duplicates. The final dataset included 93 887 samples sequenced at target k13 positions and 185 099 samples sequenced for either k13, crt K76T, or mdr1 N86Y, drawn from 578 studies encompassing 3848 distinct surveys across 47 African countries. Modelling showed distinct emergences of k13 R561H in Rwanda, k13 A675V and C469Y in Uganda, and k13 R622I in Ethiopia and Eritrea. The highest predicted prevalence of k13 mutations in 2024 was observed in Northern Province, Rwanda, at 62·2% (95% credible interval 3·9-98·6), increasing from 0·2% (0·0-0·7) in 2012 at an average annual increase of 5·2 percentage points. Modelling indicated a rapid transition from localised k13 ART-R mutation emergence to entrenched regional hot spots covering most of Uganda and Rwanda, and similarly at the border of Ethiopia, Eritrea, and Sudan. Prevalence of mdr1 N86Y, a marker of partner-drug amodiaquine reduced susceptibility, is fading, but crt K76T remains prevalent in the Horn of Africa. INTERPRETATION: The rapid, multicentric expansion of k13 ART-R mutations in east Africa threatens ACT efficacy, especially where k13 and markers of reduced susceptibility to partner drugs, such as mdr1 N86Y, or crt K76T, co-occur. This study provides an updated k13 ART-R mutation database and high-resolution resistance maps with uncertainty quantification, supporting targeted surveillance to identify hot spots and prioritise therapeutic efficacy studies. FUNDING: US National Institutes of Health.
引用
- Young NW, Meier-Scherling CPG, Cuomo-Dannenburg G, et al. Mapping the prevalence of molecular markers of Plasmodium falciparum artemisinin partial resistance in Africa: a systematic review and spatiotemporal modelling study. Lancet Infect Dis. 2026. PMID: 42413528. doi:10.1016/S1473-3099(26)00237-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。